These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 9453055

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hydrogen Bonding Interactions in Amorphous Indomethacin and Its Amorphous Solid Dispersions with Poly(vinylpyrrolidone) and Poly(vinylpyrrolidone-co-vinyl acetate) Studied Using (13)C Solid-State NMR.
    Yuan X, Xiang TX, Anderson BD, Munson EJ.
    Mol Pharm; 2015 Dec 07; 12(12):4518-28. PubMed ID: 26512737
    [Abstract] [Full Text] [Related]

  • 3. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
    Rumondor AC, Marsac PJ, Stanford LA, Taylor LS.
    Mol Pharm; 2009 Dec 07; 6(5):1492-505. PubMed ID: 19634917
    [Abstract] [Full Text] [Related]

  • 4. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
    Prasad D, Chauhan H, Atef E.
    J Pharm Sci; 2014 Nov 07; 103(11):3511-3523. PubMed ID: 25196860
    [Abstract] [Full Text] [Related]

  • 5. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization.
    Matsumoto T, Zografi G.
    Pharm Res; 1999 Nov 07; 16(11):1722-8. PubMed ID: 10571278
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers.
    Khougaz K, Clas SD.
    J Pharm Sci; 2000 Oct 07; 89(10):1325-34. PubMed ID: 10980507
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers.
    Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS.
    J Pharm Sci; 2013 Jan 07; 102(1):171-84. PubMed ID: 23132686
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state.
    Crowley KJ, Zografi G.
    Pharm Res; 2003 Sep 07; 20(9):1417-22. PubMed ID: 14567636
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thermoanalytical and Fourier transform infrared spectral curve-fitting techniques used to investigate the amorphous indomethacin formation and its physical stability in Indomethacin-Soluplus® solid dispersions.
    Lin SY, Lin HL, Chi YT, Huang YT, Kao CY, Hsieh WH.
    Int J Pharm; 2015 Dec 30; 496(2):457-65. PubMed ID: 26481469
    [Abstract] [Full Text] [Related]

  • 20. Phase Behavior of Amorphous Solid Dispersions of Felodipine: Homogeneity and Drug-Polymer Interactions.
    Sarpal K, Delaney S, Zhang GGZ, Munson EJ.
    Mol Pharm; 2019 Dec 02; 16(12):4836-4851. PubMed ID: 31682129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.